Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial

American Heart Journal

Volumn 144, Issue 4, 2002, Pages 589-596

  Tardif, Jean Claude ^a   Grégoire, Jean ^a   Lespérance, Jacques ^a   Lambert, Jean ^a   L'Allier, Philippe L ^a   Rodés, Josep ^b   Anderson, Todd ^c   Blue, John W ^d   Imus, James ^d   Heinonen, Therese ^d  

^a MONTREAL HEART INSTITUTE   (Canada)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c FOOTHILLS HOSPITAL   (Canada)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; AVASIMIBE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; HYPERLIPIDEMIA; INTRAVASCULAR ULTRASOUND; MORBIDITY; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL;

EID: 0036792162     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(02)00128-X     Document Type: Article

References (24)

1. Moreno PR, Falk E, Palacios IF, et al. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation 1994;90:775-8.
2. Erickson SK, Shrewsbury MA, Brooks C, et al. Rat liver acyl-coenzyme A: cholesterol acyltransferase: its regulation in vivo and some of its properties in vitro. J Lipid Res 1980;21:930-41.
3. Bocan TMA, Bak Mueller S, Uhlendorf PD, et al. Comparison of Cl-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions: a biochemical, morphological and morphometric evaluation. Arterioscler Thromb 1991;11:1830-43.
4. Bocan TMA, Krause BR, Rosebury WS, et al. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 2000;20:70-9.
5. Delsing DJM, Offerman EH, Duyvenvoorde WV, et al. Acyl-CoA: cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in apo E3-Leiden mice. Circulation 2001;103:1778-86.
6. Waters D, Craven TE, Lespérance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 1993;87:1067-75.
7. Tardif JC, Lee HS. Applications of intravascular ultrasound in cardiology. In: Reiber JHC, van der Wall EE, editors. What's new in cardiovascular imaging? Dordrecht: Kluwer Academic Publishers; 1998. p. 133-48.
8. Côté G, Tardif JC, Lespérance J, et al. Effects of probucol on vascular remodeling after coronary angioplasty. Circulation 1999;99:30-5.
9. Nissen S. Coronary angiography and intravascular ultrasound. Am J Cardiol 2001;87:15-20A.
10. Tardif JC, Pandian NG. Intravascular ultrasound imaging in peripheral arterial and coronary artery disease. Curr Opin Cardiol 1994;9:627-33.
11. Tardif JC, Pandian NG. Intravascular and intracardiac ultrasound. Coron Artery Dis 1995;6:33-41.
12. Tardif JC. The future of intravascular ultrasound in the detection and management of coronary artery disease. Can J Cardiol 2000; 16(D Suppl):12-5D.
13. Von Birgelen C, de Feyter PJ, de Very EA, et al. Simpson's rule for the volumetric ultrasound assessment of atherosclerotic coronary arteries: a study with ECG-gated three-dimensional intravascular ultrasound. Coron Artery Dis 1997;8:363-9.
14. Liebson PR, Klein LW. Intravascular ultrasound in coronary atherosclerosis: a new approach to clinical assessment. Am Heart J 1992;123:1643-60.
15. Tardif JC, Meerkin D, Vincent J, et al. Effects of post-PTCA brachytherapy on coronary arterial volumes: a 3-D IVUS study [abstract]. Can J Cardiol 1999;15:175D.
16. Matar FA, Mintz GS, Douek P, et al. Coronary artery lumen volume measurement using three-dimensional intravascular ultrasound: validation of a new technique. Cathet Cardiovasc Diagn 1994;33:214-20.
17. Hausmann D, Erbel R, Alibelli-Chemarin MJ, et al. The safety of intracoronary ultrasound: a multicenter survey of 2207 examinations. Circulation 1995;91:623-30.
18. Pinto FJ, St Goar F, Gao SZ, et al. Immediate and one-year safety of intracoronary ultrasonic imaging: evaluation with serial quantitative angiography. Circulation 1993;88:1709-14.
19. Sonka M, Zhang X. Assessment of plaque composition using intravascular ultrasound In: Reiber JHC, van der Wall EE, editors. What's new in cardiovascular imaging? Dordrecht: Kluwer Academic Publishers; 1998. p. 183-96.
20. Di Mario C, Gorge G, Peters R, et al. Clinical application and image interpretation in intracoronary ultrasound. Eur Heart J 1998;19:207-29.
21. Palmer ND, Northridge D, Lessells A, et al. In vitro analysis of coronary atheromatous lesions by intravascular ultrasound: reproducibility and histological correlation of lesion morphology. Eur Heart J 1999;20:1701-6.
22. Hodgson JM, Reddy KG, Suneja R, et al. Intracoronary ultrasound imaging: correlation of plaque morphology with angiography, clinical syndrome, and procedural results in patients undergoing coronary angioplasty. J Am Coll Cardiol 1993;21:35-44.
23. Tardif JC, Bertrand OF, Mongrain R, et al. Reliability of mechanical and phased-array designs for serial intravascular ultrasound examinations. Int J Card Imaging 2000;16:365-75.
24. Schartl M, Bocksch W, Koschyk DH, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001;104:387-92.